Zacks: Brokerages Expect Dynavax Technologies Co. (DVAX) to Announce -$0.51 Earnings Per Share

Analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will report ($0.51) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.47). Dynavax Technologies reported earnings of ($0.56) per share in the same quarter last year, which suggests a positive year over year growth rate of 8.9%. The firm is expected to issue its next quarterly earnings report on Monday, May 14th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($1.91) per share for the current year, with EPS estimates ranging from ($2.20) to ($1.72). For the next fiscal year, analysts expect that the firm will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.45) to ($0.54). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Dynavax Technologies.

How to Become a New Pot Stock Millionaire

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.53 million.

A number of equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, March 27th. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. Royal Bank of Canada reissued a “buy” rating and issued a $25.00 target price on shares of Dynavax Technologies in a research report on Friday, March 9th. Cowen reissued a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Wednesday, February 21st. Finally, JPMorgan Chase cut shares of Dynavax Technologies from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $31.00 to $25.00 in a research report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $24.67.

Shares of Dynavax Technologies stock traded down $0.85 during trading on Friday, reaching $18.55. The company’s stock had a trading volume of 564,941 shares, compared to its average volume of 1,499,597. The stock has a market cap of $1,205.86, a PE ratio of -10.75 and a beta of 0.84. Dynavax Technologies has a 52 week low of $5.05 and a 52 week high of $24.45.

In related news, insider David F. Novack sold 2,121 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $17.97, for a total value of $38,114.37. Following the completion of the transaction, the insider now owns 77,192 shares of the company’s stock, valued at $1,387,140.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David F. Novack sold 16,109 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $16.30, for a total value of $262,576.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,444 shares of company stock valued at $865,906. 2.90% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Dynavax Technologies by 0.7% during the fourth quarter. BlackRock Inc. now owns 3,873,883 shares of the biopharmaceutical company’s stock worth $72,441,000 after acquiring an additional 27,123 shares in the last quarter. Senvest Management LLC raised its stake in Dynavax Technologies by 29.3% during the fourth quarter. Senvest Management LLC now owns 1,541,588 shares of the biopharmaceutical company’s stock worth $28,828,000 after acquiring an additional 349,288 shares in the last quarter. Deutsche Bank AG raised its stake in Dynavax Technologies by 2.4% during the fourth quarter. Deutsche Bank AG now owns 1,426,918 shares of the biopharmaceutical company’s stock worth $26,682,000 after acquiring an additional 33,390 shares in the last quarter. Franklin Resources Inc. raised its stake in Dynavax Technologies by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 1,058,630 shares of the biopharmaceutical company’s stock worth $19,796,000 after acquiring an additional 79,900 shares in the last quarter. Finally, Clearbridge LLC acquired a new position in Dynavax Technologies during the fourth quarter worth about $10,335,000. 71.22% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3335716/zacks-brokerages-expect-dynavax-technologies-co-dvax-to-announce-0-51-earnings-per-share.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


© 2006-2018 Ticker Report. Google+.